Valion Bio, Inc. (VBIO) Form S-3 — Oct 16, 2026
Valion Bio filed an S-3 registering the resale by 3i, LP of up to 3,954,381 shares of common stock, consisting of shares issuable upon conversion of Series B and Series C preferred stock and exercise of warrants, at a fixed conversion price of $3.62. The company will receive no proceeds from resales, only warrant exercise proceeds if ever paid. The 3.95 million registrable shares compare with just 2,095,687 shares outstanding as of October 13, 2026, implying potential dilution approaching 189% of the current share base and a substantial selling-pressure overhang.
Key figures
- Offering Price
- 0
- Shares Offered
- 3954381
- Shares Outstanding
- 2095687
- Reverse split ratio
- 1-for-25
- 3i post offering percent
- 46.17%
- Closing price oct13 2026
- 1.55
- 3i prior ownership shares
- 9142842
- Warrant shares registered
- 1109442
- Preferred conversion price
- $3.62
- Series b shares registered
- 536159
- Series c offering capacity
- $75,000,000
- Series c shares registered
- 2308780
- Senior secured note principal
- $15,916,188.81
- Second side letter purchase price
- $7,737,000
- Cash received from second side letter
- $1,500,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.